Revance Therapeutics, Inc.
RVNC
|
$3.82
-3.78%
-3.93%
2.4M
|
Health Technology
(0.0% 1d) (-19.6% 1m) (-86.8% 1y) (0.0% 2d) (0.0% 3d) (-10.0% 7d) (34.45% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 398,103,645
http://www.revance.com
Sec Filling | Patents | 193 employees
(United States) Revance Therapeutics, Inc. is a clinical stage biotechnology company. It engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Newark, CA.
aesthetic
add to watch list Paper trade email alert is off
Press-releases
Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting
Published: 2024-04-12 (Crawled : 13:00) - biospace.com/
VTRS | $11.12 -1.77% -1.8% 6.8M
|
Health Technology
|
| O: -0.17%
H: 0.17%
C: -1.9%
RVNC | $3.82 -3.78% -3.93% 2.4M
|
Health Technology
|
| O: -2.01%
H: 1.37%
C: -5.92%
daxxify neurology meeting
Revance Announces Pricing of $100.0 Million Public Offering of Common Stock
Published: 2024-03-04 (Crawled : 17:00) - biospace.com/
VTRS | $11.12 -1.77% -1.8% 6.8M
|
Health Technology
|
| O: 0.0%
H: 0.08%
C: -1.83%
RVNC | $3.82 -3.78% -3.93% 2.4M
|
Health Technology
|
| O: -11.6%
H: 3.89%
C: -1.62%
million offering
Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024
Published: 2024-02-21 (Crawled : 15:30) - biospace.com/
VTRS | $11.12 -1.77% -1.8% 6.8M
|
Health Technology
|
| O: -0.15%
H: 0.76%
C: 0.3%
RVNC | $3.82 -3.78% -3.93% 2.4M
|
Health Technology
|
| O: 0.18%
H: 0.72%
C: -2.72%
year financial results
Global Cell Penetrating Peptide Market Forecast Report to 2030, Featuring Biosynth, Creative Peptides, Cupid Peptide, Alta Bioscience, AnaSpec, Peptomyc, PolyPeptide, Bachem & Sarepta Therapeutics
Published: 2024-02-05 (Crawled : 11:00) - prnewswire.com
SRPT | $117.27 -0.88% -0.89% 590K
|
Health Technology
|
| O: 0.12%
H: 3.45%
C: 3.4%
RVNC | $3.82 -3.78% -3.93% 2.4M
|
Health Technology
|
| O: -2.42%
H: 1.05%
C: -2.67%
report cell global therapeutics market
Revance to Participate in the Guggenheim 6th Annual Biotechnology Conference
Published: 2024-02-01 (Crawled : 21:00) - biospace.com/
VTRS | $11.12 -1.77% -1.8% 6.8M
|
Health Technology
|
| O: -0.42%
H: 1.75%
C: 1.28%
RVNC | $3.82 -3.78% -3.93% 2.4M
|
Health Technology
|
| O: 1.59%
H: 4.11%
C: 0.78%
conference
Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook
Published: 2024-01-08 (Crawled : 14:00) - biospace.com/
VTRS | $11.12 -1.77% -1.8% 6.8M
|
Health Technology
|
| O: -0.83%
H: 0.72%
C: -1.43%
RVNC | $3.82 -3.78% -3.93% 2.4M
|
Health Technology
|
| O: -13.17%
H: 3.45%
C: -2.76%
year financial
Revance to Release Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
Published: 2023-11-01 (Crawled : 13:00) - biospace.com/
VTRS | $11.12 -1.77% -1.8% 6.8M
|
Health Technology
|
| O: -0.45%
H: 0.96%
C: 0.68%
RVNC | $3.82 -3.78% -3.93% 2.4M
|
Health Technology
|
| O: -0.63%
H: 1.66%
C: 1.15%
financial results
Global Facial Injectable Market Analysis Report 2023-2028: New Product Launches, Increased Male Aesthetics, and Emerging Markets Driving Growth
Published: 2023-09-06 (Crawled : 10:00) - prnewswire.com
ABBV | $162.54 0.54% 0.0% 4.8M
|
Health Technology
|
| O: -0.1%
H: 0.0%
C: 0.0%
RVNC | $3.82 -3.78% -3.93% 2.4M
|
Health Technology
|
| O: -0.46%
H: 1.38%
C: -2.87%
EOLS | $12.05 1.35% 1.33% 500K
|
Health Technology
|
| O: 0.41%
H: 0.92%
C: -0.1%
report global growth market
Revance to Host Investor Day on September 19, 2023
Published: 2023-08-22 (Crawled : 14:00) - biospace.com/
VTRS | $11.12 -1.77% -1.8% 6.8M
|
Health Technology
|
| O: -0.18%
H: 0.45%
C: -0.62%
RVNC | $3.82 -3.78% -3.93% 2.4M
|
Health Technology
|
| O: 0.28%
H: 2.33%
C: 1.65%
day
U.S. FDA Approves First Therapeutic Indication for Revance’s DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia
Published: 2023-08-14 (Crawled : 13:00) - biospace.com/
VTRS | $11.12 -1.77% -1.8% 6.8M
|
Health Technology
|
| O: -0.35%
H: 0.0%
C: -1.06%
RVNC | $3.82 -3.78% -3.93% 2.4M
|
Health Technology
|
| O: 6.13%
H: 1.54%
C: -3.04%
daxxify fda treatment injection
Last 15 days Sec forms
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 58% | 42% |
Top 10 Gainers
WISA 4 | $6.06 246.29% 71.12% 200M
|
Electronic Technology
VIAO | $0.265 -13.96% 35.85% 960K
|
Electronic Technology
JAGX | $0.178 49.83% 33.26% 600M
|
Health Technology
SXTC | $1.68 43.59% 30.36% 34M
|
Health Technology
DYNT | $0.531 43.36% 30.24% 22M
|
Health Technology
KA | $0.4796 41.06% 29.11% 5.3M
|
Manufacturing
PALI | $5.86 40.87% 29.01% 29M
|
Manufacturing
CLNN | $0.319 -3.74% 28.75% 6.3M
|
BSGM | $1.52 38.18% 27.63% 3.3M
|
Health Technology
MCBC | $13.67 37.66% 27.36% 2.2M
|
Finance
Last 48 Hours Insiders Buying
KFS P 481 | $8.6 1.06% 0.0% 15K
|
Finance
|
20:30
AINC | $4.83 -1.43% -1.04% 81K
|
Finance
|
20:30
RVP P 3587 | $1.065 -1.39% 0.47% 49K
|
Health Technology
|
17:00
TPL P 12 | $586.93 0.52% 0.0% 50K
|
Miscellaneous
|
16:01
HNRA | $2.76 16.95% -1.81% 400K
|
n/a
|
15:02
TGEN | $0.67 39.71% 16K
|
Utilities
|
14:30
RMCF | $3.6492 -7.2% 9.2K
|
Consumer Non-Durables
|
20:10